115 related articles for article (PubMed ID: 9396618)
41. Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo.
Vincent TS; Hazen-Martin DJ; Garvin AJ
Cancer Lett; 1996 May; 103(1):49-56. PubMed ID: 8616808
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution.
Kim JH; Sherwood ER; Sutkowski DM; Lee C; Kozlowski JM
J Urol; 1991 Jul; 146(1):171-6. PubMed ID: 2056586
[TBL] [Abstract][Full Text] [Related]
43. Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity.
Baghdiguian S; Nickel P; Fantini J
Cancer Lett; 1991 Dec; 60(3):213-9. PubMed ID: 1756511
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the pharmacological antitumor effects of S 12363, a new vinca alkaloid.
Atassi G; Berlion M; el Oche Y; Bizzari JP
Anticancer Res; 1991; 11(2):975-80. PubMed ID: 2064354
[TBL] [Abstract][Full Text] [Related]
45. Effect of suramin on differentiation of human stomach cancer cell lines.
Choe G; Kim WH; Park JG; Kim YI
J Korean Med Sci; 1997 Oct; 12(5):433-42. PubMed ID: 9364302
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.
Wang LL; Li JJ; Zheng ZB; Liu HY; Du GJ; Li S
Eur J Pharmacol; 2004 Oct; 502(1-2):1-10. PubMed ID: 15464084
[TBL] [Abstract][Full Text] [Related]
47. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis.
Pepper MS; Vassalli JD; Wilks JW; Schweigerer L; Orci L; Montesano R
J Cell Biochem; 1994 Aug; 55(4):419-34. PubMed ID: 7525617
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
49. The effect of suramin, tumor necrosis factor and interferon gamma on human prostate carcinoma.
Liu S; Ewing MW; Anglard P; Trahan E; La Rocca RV; Myers CE; Linehan WM
J Urol; 1991 Feb; 145(2):389-92. PubMed ID: 1899122
[TBL] [Abstract][Full Text] [Related]
50. Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response.
Leland P; Obiri N; Aggarwal BB; Puri RK
Oncol Res; 1995; 7(5):227-35. PubMed ID: 8534928
[TBL] [Abstract][Full Text] [Related]
51. [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
Zhang P; He JB; Ou LW; Wang XH
Ai Zheng; 2006 Apr; 25(4):409-13. PubMed ID: 16613671
[TBL] [Abstract][Full Text] [Related]
52. Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor.
Fujiuchi S; Ohsaki Y; Kikuchi K
Oncology; 1997; 54(2):134-40. PubMed ID: 9075785
[TBL] [Abstract][Full Text] [Related]
53. Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients.
Csoka K; Nygren P; Graf W; Påhlman L; Glimelius B; Larsson R
Int J Cancer; 1995 Nov; 63(3):356-60. PubMed ID: 7591231
[TBL] [Abstract][Full Text] [Related]
54. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.
Minniti CP; Maggi M; Helman LJ
Cancer Res; 1992 Apr; 52(7):1830-5. PubMed ID: 1312901
[TBL] [Abstract][Full Text] [Related]
55. Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Yamazaki H; Dilworth A; Myers CE; Sinha BK
Prostate; 1993; 23(1):25-36. PubMed ID: 8393191
[TBL] [Abstract][Full Text] [Related]
56. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
57. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
58. In-vitro toxicity assessment of a textile dye Eriochrome Black T and its nano-photocatalytic degradation through an innovative approach using Mf-NGr-CNTs-SnO
De I; Pahuja M; Ud Din Wani HM; Dey A; Dube T; Ghosh R; Kankan N; Mishra J; Panda JJ; Maruyama T; Ghosh K; Singh M
Ecotoxicol Environ Saf; 2022 Sep; 243():113985. PubMed ID: 36027712
[TBL] [Abstract][Full Text] [Related]
59. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Lu Z; Wientjes TS; Au JL
Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
[TBL] [Abstract][Full Text] [Related]
60. [The effect of suramin on human lung cancer cell line in vitro].
Fujiuchi S; Tsuji T; Ohsaki Y; Kikuchi K
Gan To Kagaku Ryoho; 1994 Apr; 21(5):647-52. PubMed ID: 8154891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
